QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Filters
Save & Share
Clear Filters
Location
Explore options near your home - or near family and friends.
Diagnosis
Treatment History
Prior BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 35 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Not yet accepting
- Not yet accepting
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsUCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Accepting patients
- Accepting patients
- Accepting patients
- Not yet accepting
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
- Not yet accepting
University of Kansas Cancer Center
Kansas City, KS
- Accepting patients
- Accepting patients
Massachusetts General Hospital
Boston, MA
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.